Agenus - mark

At Agenus, we believe the best path for treating disease is through activating our own body’s natural mechanisms.

That’s why for 20 years, we’ve focused on building technologies and a product pipeline aimed at treating cancer and infectious disease by helping the body’s immune system target diseased cells with precision.

  • May 21, 2015

    Agenus Announces Pricing of Its Public Offering of Common Stock
    Read More

     

  • May 20, 2015

    Agenus Announces Proposed Public Offering of Common Stock
    Read More

     

  • May 14, 2015

    Agenus Announces Oral Presentation at ASCO Highlighting Improved Survival with Prophage Immunotherapy in Brain Cancer Compared to Historical Controls
    Read More

     

  • May 8, 2015

    Agenus to Host Research and Development Day on May 14, 2015
    Read More

     

  • April 28, 2015

    NEJM Publishes Study Showing GSK’s Shingles Vaccine Containing Agenus’ QS-21 Stimulon® Adjuvant Provides over 97% Protection in People Over the Age of 50
    Read More

     

  • April 24, 2015

    GSK’s Malaria Vaccine Phase 3 Study Containing Agenus’ QS-21 Published in The Lancet
    Read More

     

  • April 8, 2015

    Agenus Acquires Celexion Assets and Expands Its Antibody Discovery Platform
    Read More

     

  • January 9, 2015

    Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies
    Read More

     

  • December 18, 2014

    Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant
    Read More